KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) EBT (2016 - 2025)

Pacira BioSciences (PCRX) has 16 years of EBT data on record, last reported at $571000.0 in Q4 2025.

  • For Q4 2025, EBT fell 97.76% year-over-year to $571000.0; the TTM value through Dec 2025 reached $16.9 million, up 126.74%, while the annual FY2025 figure was $16.9 million, 126.74% up from the prior year.
  • EBT reached $571000.0 in Q4 2025 per PCRX's latest filing, down from $9.5 million in the prior quarter.
  • Across five years, EBT topped out at $37.9 million in Q2 2023 and bottomed at -$138.9 million in Q3 2024.
  • Average EBT over 5 years is $4.3 million, with a median of $11.1 million recorded in 2021.
  • Peak YoY movement for EBT: surged 702.37% in 2023, then plummeted 936.43% in 2024.
  • A 5-year view of EBT shows it stood at -$6.2 million in 2021, then tumbled by 191.51% to -$18.1 million in 2022, then soared by 286.63% to $33.7 million in 2023, then decreased by 24.3% to $25.5 million in 2024, then tumbled by 97.76% to $571000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for EBT were $571000.0 in Q4 2025, $9.5 million in Q3 2025, and -$1.9 million in Q2 2025.